Neuronetics Inc. Appoints Nir Naor As Chief Financial Officer

Company

Location

About

The Company today announced that it has entered into an amendment to its senior secured credit facilities with SLR, which collectively provide for borrowings of up to $60.0 million, comprised of $37.5 million in three tranches of term loans, a “Term A Loan” in an aggregate amount of $35.0 million, a “Term B Loan” in an aggregate amount of $2.5 million, and a “Term C Loan” in an aggregate amount of $22.5 million. The incremental capital will further strengthen our balance sheet, allowing the company to drive the continued commercial adoption of NeuroStar Advanced Therapy for Mental Health and with the continued goal of achieving cash flow breakeven in 2024,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today provided a corporate update which includes entering into a new credit facility with investment affiliates managed by SLR Capital Partners, LLC (“SLR”) and providing Greenbrook TMS (“Greenbrook”) with a promissory note as part of an updated TMS device supply agreement. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.